New Study Shows Aspirin May Lower the Risk of Ovarian Cancer
Orange County, CA - October 5th, 2018 - Early-stage Ovarian Cancer rarely causes any symptoms. It often goes undetected until it has spread within the pelvis and abdomen. Ovarian cancer found at an earlier stage where the disease is confined to the ovary could be treated successfully. Advanced-stage ovarian cancer may cause few and nonspecific symptoms that are often mistaken for more common benign conditions; it can be more difficult to treat and is usually fatal.
It is not clear what causes ovarian cancer; doctors have identified factors that increase the risk of the disease such as old age, inherited gene mutations, or family history. A new study published by JAMA Oncology found that women who reported taking a low-dose aspirin every day had a 23 percent lower risk of ovarian cancer compared to non-aspirin users.
The study involved associate center director for Population Science at Moffitt, Shelley Tworoger, Ph.D. work with researchers at Huntsman Cancer Institute, and the Harvard T.H. Chan School of Public Health. They examined data from over 200,000 women who participated in the Nurses' Health Studies based at Brigham, and Women's Hospital in Boston.
Of the study participants, 1,054 developed ovarian cancer. Researchers looked at the use of low-dose aspirin (100 milligrams or less), aspirin (325 milligrams), non-aspirin NSAIDs, and acetaminophen. They discovered that low-dose aspirin use was associated with a lower risk of ovarian cancer while standard-dose aspirin use was not. However, the information showed women who took non-aspirin NSAIDs often, defined by at least 10 tablets per week for many years, had an increased risk of developing ovarian cancer.
"We're not quite at the stage where we could make the recommendation that daily aspirin use lowers ovarian cancer risk. We need to do more research. But it is definitely something women should discuss with their physician," said Shelley Tworoger, Ph.D
The discovery helps confirm research published in the Journal of the National Cancer Institute earlier this year. The study used information from 13 studies in the Ovarian Cancer Cohort Consortium, which included over 750,000 women. Of those women, 3,500 were diagnosed with ovarian cancer. The study found that daily use of aspirin reduced ovarian cancer risk by 10 percent.
Contact Ampronix:
Email: [email protected]
International Sales: +1 949-273-8000
Domestic Sales: 1800-400-7972 for US and Canada
Follow Us:
Facebook, Twitter, LinkedIn
Share This Article:
View our Product Catalog Online Here
About Ampronix
Ampronix is a renowned authorized master distributor of the medical industry's top brands as well as a world-class manufacturer of innovative technology. Since 1982, Ampronix has been dedicated to meeting the growing needs of the medical community with its extensive product knowledge, outstanding service, and state-of-the-art repair facility. Ampronix prides itself on its ability to offer tailored, one-stop solutions at a faster and more cost-effective rate than other manufacturers. Ampronix is ISO 13485:2003, and ANSI/ESD S20.20-2014 certified.
